Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry October 09, 2024 — 11:00 am EDT Written by Benzinga Insights for Benzinga -> ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Humana accused Regeneron of inflating the drug's price from $1,500 a dose to $1,950 by partnering with the charity, the Chronic Disease Foundation, to cover patients' cost-sharing obligations for ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Going up against a giant. Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset.

Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal ... The two organizations argued there was no competitive overlap with their respective medicines and criticized the FTC’s theory ...

Dynamically explore and compare data on law firms ... Pharma Co. Hit With Antitrust Suit for Allegedly Blocking Sale of Competitor's Cholesterol Med 1 minute ... Regeneron Pharmaceuticals, Inc ...

Humana accused Regeneron of inflating the drug's price from $1,500 a dose to $1,950 by partnering with the charity, the Chronic Disease Foundation, to cover patients' cost-sharing obligations for ...